Insight Molecular Diagnostics (IMDX) Total Liabilities (2015 - 2026)

Insight Molecular Diagnostics has reported Total Liabilities for 12 years, with the latest figure at $51.1 million in Q1 2026.

• Quarterly Total Liabilities rose 1.95% year-over-year to $51.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.1 million (up 1.95% YoY) and the FY2025 annual result came in at $57.2 million, up 20.83% from the prior year.
• Total Liabilities retreated to $51.1 million in Q1 2026 per IMDX's latest filing, from $57.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $89.3 million in Q1 2022 and troughed at $39.1 million in Q3 2023.
• A 5-year average of $55.9 million and a median of $52.0 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 293.82% in 2022, then slumped 55.95% in 2023.
• Over 5 years, Total Liabilities stood at $60.5 million in 2022, then dropped by 18.51% to $49.3 million in 2023, then retreated by 3.94% to $47.4 million in 2024, then gained by 20.83% to $57.2 million in 2025, then dropped by 10.66% to $51.1 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $51.1 million, $57.2 million, and $53.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.